source
- Tarsus to acquire Alkeus for $450 million, adding phase-3 retinal drug and oral Stargardt candidateTarsus Pharmaceuticals announced it will buy Alkeus Pharmaceuticals in a transaction valued at $450 million. The deal consists of $270 million in cash and $180 million of Tarsus common stock, givi…
- FDA approves first drug for type 1 narcolepsy and greenlights mRNA flu vaccine; AstraZeneca and BMS deny merger talksThe U.S. Food and Drug Administration has granted approval for the first therapy specifically targeting type 1 narcolepsy, marking a milestone for patients with this rare sleep disorder. In a sepa…